41 research outputs found
Irbesartan in patients with heart failure and preserved ejection fraction.
Background
Approximately 50% of patients with heart failure have a left ventricular ejection
fraction of at least 45%, but no therapies have been shown to improve the outcome
of these patients. Therefore, we studied the effects of irbesartan in patients with
this syndrome.
Methods
We enrolled 4128 patients who were at least 60 years of age and had New York Heart
Association class II, III, or IV heart failure and an ejection fraction of at least 45%
and randomly assigned them to receive 300 mg of irbesartan or placebo per day.
The primary composite outcome was death from any cause or hospitalization for a
cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia,
or stroke). Secondary outcomes included death from heart failure or
hospitalization for heart failure, death from any cause and from cardiovascular
causes, and quality of life.
Results
During a mean follow-up of 49.5 months, the primary outcome occurred in 742
patients in the irbesartan group and 763 in the placebo group. Primary event rates
in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years,
respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P = 0.35).
Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard
ratio, 1.00; 95% CI, 0.88 to 1.14; P = 0.98). Rates of hospitalization for cardiovascular
causes that contributed to the primary outcome were 70.6 and 74.3 per
1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P = 0.44).
There were no significant differences in the other prespecified outcomes.
Conclusions
Irbesartan did not improve the outcomes of patients with heart failure and a preserved
left ventricular ejection fraction
Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients’ own inflammatory cells, platelets and growth factors : the first introduction to the low speed centrifugation concept
Purpose: The aim of this study was to analyze systematically the influence of the relative centrifugation force (RCF) on leukocytes, platelets and growth factor release within fluid platelet-rich fibrin matrices (PRF).
Materials and methods: Systematically using peripheral blood from six healthy volunteers, the RCF was reduced four times for each of the three experimental protocols (I–III) within the spectrum (710–44 g), while maintaining a constant centrifugation time. Flow cytometry was applied to determine the platelets and leukocyte number. The growth factor concentration was quantified 1 and 24 h after clotting using ELISA.
Results: Reducing RCF in accordance with protocol-II (177 g) led to a significantly higher platelets and leukocytes numbers compared to protocol-I (710 g). Protocol-III (44 g) showed a highly significant increase of leukocytes and platelets number in comparison to -I and -II. The growth factors’ concentration of VEGF and TGF-β1 was significantly higher in protocol-II compared to -I, whereas protocol-III exhibited significantly higher growth factor concentration compared to protocols-I and -II. These findings were observed among 1 and 24 h after clotting, as well as the accumulated growth factor concentration over 24 h.
Discussion: Based on the results, it has been demonstrated that it is possible to enrich PRF-based fluid matrices with leukocytes, platelets and growth factors by means of a single alteration of the centrifugation settings within the clinical routine.
Conclusions: We postulate that the so-called low speed centrifugation concept (LSCC) selectively enriches leukocytes, platelets and growth factors within fluid PRF-based matrices. Further studies are needed to evaluate the effect of cell and growth factor enrichment on wound healing and tissue regeneration while comparing blood concentrates gained by high and low RCF